Anticancer Medicine and Cancer Immunotherapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 83
Special Issue Editor
Special Issue Information
Dear Colleagues,
Anticancer medicine and cancer immunotherapy is a multifaceted topic focusing on the latest advancements and strategies in combating cancer. The scope of this topic encompasses the development and application of anticancer medicine, specifically designed to hinder the growth and spread of cancer cells. The scope includes chemotherapy agents, targeted therapies and hormonal treatments, each with distinct mechanisms of action and efficacy profiles.
A significant part of the discussion revolves around cancer immunotherapy, an innovative treatment approach that harnesses the body's immune system to fight cancer. This segment would cover various types of immunotherapies, such as checkpoint inhibitors, CAR T-cell therapies and cancer vaccines, elucidating their roles in activating or enhancing the immune response against cancer cells.
The scope also entails an exploration of challenges and breakthroughs in these fields, including the issues of drug resistance, side effects and the development of personalized medicine strategies. The potential synergy between anticancer drugs and immunotherapy, aiming to enhance treatment effectiveness and patient outcomes, is a crucial aspect.
Furthermore, the topic would address the ongoing research and clinical trials that are paving the way for new treatments, alongside the ethical and economic considerations involved in the development and accessibility of these advanced therapies. The goal is to provide a comprehensive overview of the current landscape and future prospects of anticancer medicine and cancer immunotherapy, highlighting their pivotal roles in the evolving fight against cancer.
Prof. Dr. Chao-Liang Wu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer
- cancer immunotherapy
- CAR T-cell therapies
- targeted therapies
